The purpose of the study is to evaluate how well this combination treatment works in patients whose cancers have progressed or become resistant after at least one standard treatment. The study will involve patients receiving the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 24 weeks, during which the effectiveness and safety of the treatment will be closely monitored. Patients will be grouped into different cohorts based on their specific type of cancer, and the study will assess various outcomes, such as the rate of cancer progression and overall survival.

Throughout the study, researchers will collect data to understand how the treatment affects the different types of rare cancers. The goal is to determine if the combination of Domvanalimab and Zimberelimab can provide a new and effective treatment option for patients with these challenging conditions. The study is part of a larger effort to explore innovative therapies for rare cancers, which often have limited treatment options. By participating in this trial, researchers hope to gather valuable information that could lead to improved care for patients with these rare and advanced cancers.

The purpose of the study is to assess how well these treatments work when used together with a surgical procedure called Cytoreductive Surgery and a heated chemotherapy treatment known as Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Participants in the study will receive these treatments over a period of time, with Nivolumab and MesoPher being administered before and after the surgery. The study will monitor the participants’ health and the progression of the disease throughout the treatment period.

During the study, researchers will evaluate how the treatments affect the cancer and the immune system. They will look at how long participants live without the disease getting worse and will also check for any side effects. The study aims to provide valuable information on the potential benefits of combining these innovative treatments for patients with Peritoneal Mesothelioma.

The purpose of the study is to understand if Tremelimumab can help people live longer when they have this type of cancer that cannot be removed by surgery. Participants in the study will receive either Tremelimumab or a placebo, and their health will be monitored over time to see how they respond to the treatment. The study will last for a period of up to 36 months, during which participants will have regular check-ups and tests to track their progress and any side effects they might experience.

Throughout the study, researchers will also look at other important factors, such as how the treatment affects the quality of life and any potential side effects. The study aims to provide valuable information about the safety and effectiveness of Tremelimumab for treating unresectable malignant mesothelioma, which could help improve future treatment options for this challenging condition.

The purpose of the study is to see how effective Talazoparib is in keeping the cancer from getting worse for at least six months after starting the treatment. Patients will first receive at least four cycles of chemotherapy before beginning the Talazoparib treatment. The study will follow patients to monitor their progress and see if the cancer remains stable. Some patients will receive a placebo instead of Talazoparib to compare the results.

Participants in the study will be divided into three groups, or cohorts, based on the type of mesothelioma they have. The study will last for several years, and during this time, patients will have regular check-ups and tests to track their health and the status of their cancer. The goal is to gather information that could help improve treatment options for people with mesothelioma in the future.